Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)
Summary
The awarded CIRM funding will support CMC and process development efforts and position the company for a successful pre-IND meeting at the completion of the award.Were thrilled and honored to receive this support from CIRM, said Nicole Paulk, PhD, Siren Biotechnologys CEO and Founder. We are the pioneers of Universal AAV Immuno-Gene Therapy, which combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality which we believe will redefine how we destroy tumor cells and elicit anti-tumor immunity. Our vision is for Universal AAV Immuno-Gene Therapy to become the standard of care for any solid tumor cancer.To learn more, visit sirenbiotechnology.com, and follow us on LinkedIn and Twitter.About California Institute for Regenerative Medicine (CIRM)At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of todays most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is one of the worlds largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality.For more information go to www.cirm.ca.gov.